Clinical Trial Update: Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. [Phase 2]

View source ↗

Summary

A Phase II trial in higher-risk myelodysplastic syndromes evaluating azacitidine with or without deferasirox has been terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: High Risk MDS | Phase 2 | Status: TERMINATED | Results posted: 2017-02-06